BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 28, 2018--
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Michael Goldstein, M.D., M.B.A., Chief Medical Officer of
Ocular Therapeutix, will present at the Cowen and Company 38th Annual
Health Care Conference on Wednesday, March 14, 2018 at 8:40 AM ET at the
Boston Marriott Copley Place in Boston, Massachusetts.
In addition to the presentation, the management team will host investor
meetings at the conference. Investors attending the conference who are
interested in meeting with Ocular Therapeutix management should contact
their Cowen and Company representative.
A live webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
hydrogel-based formulation technology. Ocular Therapeutix’s lead product
candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular
use, has completed Phase 3 clinical development for the treatment of
ocular pain and inflammation following ophthalmic surgery. OTX-TP
(travoprost insert) is in Phase 3 clinical development for the reduction
of intraocular pressure in patients with glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral injection for the reduction of
intraocular pressure in patients with glaucoma and ocular hypertension,
as well as sustained release intravitreal injections for the treatment
of retinal diseases. These injections include the development of
OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with
Regeneron, an extended release protein-based anti-vascular endothelial
growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005367/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix
Donald Notman
Chief
Financial Officer
dnotman@ocutx.com
or
Westwicke
Partners
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com
or
Media
Ocular
Therapeutix
Scott Corning
Vice President of Marketing &
Commercial Operations
scorning@ocutx.com
